中基健康(000972) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥24,893,658.36, a 100.00% increase compared to the same period last year when there was no revenue[3] - The net profit attributable to shareholders was -¥4,986,755.44, an improvement from -¥19,979,751.27 in the previous year, indicating a 75.01% reduction in losses[3] - The net profit for the first quarter of 2022 was -4,995,605.10 CNY, compared to -19,988,180.25 CNY in the same period last year, showing a significant improvement[19] - The total comprehensive income for the first quarter was -4,995,605.10 CNY, compared to -19,988,180.25 CNY in the previous year, indicating a reduction in losses[20] - Basic and diluted earnings per share were both -0.0065 CNY, an improvement from -0.0259 CNY in the same quarter of the previous year[20] - The company reported operating profit of -5,017,714.54 CNY, an improvement from -19,992,428.02 CNY in the same period last year[19] Cash Flow and Liquidity - The net cash flow from operating activities was ¥42,976,551.37, a significant recovery from -¥25,390,802.51 in the same period last year[3] - Cash flow from operating activities generated a net inflow of 42,976,551.37 CNY, a turnaround from a net outflow of -25,390,802.51 CNY in the previous year[21] - Cash and cash equivalents at the end of the period totaled 63,204,247.88 CNY, up from 10,548,551.53 CNY at the end of the previous year[22] - The company's cash and cash equivalents rose by 208.05% to ¥63,204,247.88 due to increased sales and recovery of previous year receivables[7] Assets and Liabilities - Total assets increased by 3.45% to ¥699,343,986.21 compared to the end of the previous year[3] - Total assets as of March 31, 2022, were CNY 699,343,986.21, up from CNY 676,041,526.27 at the beginning of the year, reflecting an increase of 3.4%[16] - Total liabilities increased to CNY 630,002,798.51 from CNY 601,705,050.46, marking a rise of 4.7%[15] - The company's total equity decreased to CNY 69,341,187.70 from CNY 74,336,475.81, a decline of 6.7%[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 28,338[10] - The top three shareholders hold a combined 35.65% of the company's shares, indicating significant ownership concentration[10] Operating Costs and Expenses - Total operating costs for Q1 2022 amounted to CNY 30,042,866.00, an increase from CNY 20,017,428.02 year-on-year[18] - Financial expenses for Q1 2022 were CNY 3,982,040.04, compared to CNY 1,345,108.05 in the previous year, indicating a significant increase[18] - Research and development expenses were CNY 458.49, with no prior year comparison available[18] Receivables and Inventory - The accounts receivable increased by 132.04% to ¥9,177,723.68, reflecting higher sales activity[7] - Accounts receivable decreased to CNY 126,855,321.23 from CNY 135,604,961.65, a decline of 6.0%[13] - Inventory decreased to CNY 151,678,614.40 from CNY 160,812,447.35, a reduction of 5.8%[14] Government Subsidies - The company received government subsidies amounting to ¥89,218.29, contributing to its non-operating income[5] Investment Activities - The total cash outflow from investing activities was -18,960.00 CNY, compared to -732,049.14 CNY in the previous year, indicating reduced investment losses[22] - The company paid 270,000.00 CNY in financing activities, compared to 344,999.99 CNY in the previous year, reflecting a decrease in financing costs[22]